2型糖尿病患者的微血管病变和系统性阿尔多 - 列宁比 (ARR) - 一个回顾性的真实世界研究
Song Wen1,2, Zhimin Xu1, Min Gong1
1Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Pudong Medical Center, Shanghai, 201399, People's Republic of China.
Diabetes, metabolic syndrome and obesity : targets and therapy
|November 20, 2025
概括
不平衡的阿尔多与素比率 (ARR) 与2型糖尿病的损伤有关. 这个比率可能有助于预测功能和尿动白蛋白与肌素比率 (UACR) 的变化.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 糖尿病学 糖尿病学
背景情况:
- 2型糖尿病 (T2DM) 是慢性病的主要原因.
- 脏微血管病是T2DM的一个常见并发症.
- 阿尔多与素的比率 (ARR) 在心血管和脏健康方面发挥着作用.
研究的目的:
- 调查T2DM患者中不平衡的阿尔多与素比率 (ARR) 和脏微血管病变之间的关联.
- 探索ARR作为T2DM中功能和损伤的潜在预测因素.
主要方法:
- 从471名T2DM患者 (2019-2023) 的数据进行了回顾性分析.
- 患者根据血红素度 (PDC) 或血红素活性 (PRA) 测量进行分类.
- 使用血清肌素 (SCr),血液尿素 (BUN),囊素C (Cys),尿中的白蛋白与肌素比率 (UACR) 和估计的淋巴膜过率 (eGFR) 评估脏微血管损伤.
主要成果:
- 在极端ARR四分位数中观察到微血管损伤标志物 (SCr,BUN) 的显著增加.
- ARR与性别,静脉血压 (SBP) 和功能标志物有显著的相关性.
- 多线性回归确定了影响ARR的因素,包括胰岛素,抗高血压药物,,血压,甲状腺激素,,葡萄糖代谢和胆酸.
- 接收器操作特征 (ROC) 曲线分析表明ARR对功能和UACR的预测值.
结论:
- 异常ARR与T2DM中的球球膜损伤有关.
- 可以利用ARR来评估损伤与氨酸-血管酶-氨系统 (RAAS) 活性之间的关系.
- 在T2DM患者中,ARR可以作为监测T2DM患者脏健康的宝贵生物标志物.
相关概念视频
Antihypertensive Drugs: Direct Renin Inhibitors
1.3K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
Nephrotic Syndrome II : Assessment and Medical Management
184
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
184
Hypertension III: Clinical Manifestations and Diagnostic Studies
451
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
451
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Hypertension II: Pathophysiology
763
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
763
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
895
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
895


